Diagnostic revision of 206 adult gliomas (including 40 oligoastrocytomas) based on ATRX, IDH1/2 and 1p/19q status

被引:0
作者
Marta Mellai
Laura Annovazzi
Rebecca Senetta
Carmine Dell’Aglio
Marta Mazzucco
Paola Cassoni
Davide Schiffer
机构
[1] Policlinico di Monza Foundation,Research Center
[2] FPO,Unit of Pathology, Candiolo Cancer Institute
[3] IRCCS Candiolo,Department of Medical Sciences
[4] University of Turin,undefined
来源
Journal of Neuro-Oncology | 2017年 / 131卷
关键词
Oligoastrocytoma; ATRX; IDH; 1p/19q co-deletion; ALT;
D O I
暂无
中图分类号
学科分类号
摘要
The diagnosis of 206 low and high grade adult gliomas, including 40 oligoastrocytomas, was revised based on the immunohistochemical reactivity for the ATRX protein, IDH1/2 mutation status and 1p/19q chromosomal status. All oligodendrogliomas kept the initial diagnosis. Astrocytomas did not change diagnosis in 30 of 36 cases (83.3 %); four of 36 (11.1 %) cases were reclassified as oligodendroglioma, one (2.8 %) as DNT and the other (2.8 %) as reactive gliosis. Oligoastrocytomas changed diagnosis in 35 of 40 (87.5 %) cases, being reclassified 22 of 40 (55 %) as astrocytoma, 11 of 40 (27.5 %) as oligodendroglioma and two of 40 (5 %) as reactive gliosis. Four (10 %) remained unclassifiable. In one case only (2.5 %), the diagnosis of oligoastrocytoma could not be excluded since tumor astrocytes and tumor oligodendrocytes coexisted in mixed tumor areas. In the GBM tumor subgroup, GBMO disappeared because they were not substantiated by molecular genetics. Pilocytic astrocytomas retained ATRX expression. Loss of nuclear ATRX protein expression was strongly associated to IDH1/2 mutations (p = 0.0001) and mutually exclusive with total 1p/19q co-deletion (p = 0.0001). In astrocytic tumors, loss of immunoreactivity for the ATRX protein was significantly associated to the ALT phenotype (p = 0.0003). The constitutive ATRX expression in microglia/macrophages may be misleading, especially in the identification of an oligodendroglial tumor infiltration. Of paramount importance in the recognition of oligodendroglial and astrocytic tumor cells were the double immunostainings for ATRX/GFAP, ATRX/IDH1R132H, ATRX/Iba-1 and ATRX/CD68.
引用
收藏
页码:213 / 222
页数:9
相关论文
共 189 条
  • [21] Eng LF(2014)Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma Acta Neuropathol 128 551-146
  • [22] Rubinstein LJ(2015)ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an “integrated” diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma Acta Neuropathol 129 133-435
  • [23] van der Meulen JD(2014)International Society Of Neuropathology-Haarlem consensus guidelines for nervous system tumor classification and grading Brain Pathol 24 429-6937
  • [24] Houthoff HJ(2007)Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker? Clin Cancer Res 13 6933-357
  • [25] Ebels EJ(2011)IDH1 and IDH2 mutations, immunohistochemistry and associations in a series of brain tumors J Neurooncol 105 345-161
  • [26] Herpers MJ(2001)Cyclin D1 expression in normal oligodendroglia and microglia cells: its use in the differential diagnosis of oligodendrogliomas Neuropathology 21 155-149
  • [27] Budka H(2015)Oligoastrocytomas: throwing the baby out with the bathwater? Acta Neuropathol 129 147-153
  • [28] Choi BH(2015)Mixed glioma with molecular features of composite oligodendroglioma and astrocytoma: a true “oligoastrocytoma”? Acta Neuropathol 129 151-4154
  • [29] Kim RC(2009)Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas J Clin Oncol 27 4150-773
  • [30] Heaphy CM(2009)IDH1 and IDH2 mutations in gliomas N Engl J Med 360 765-474